The Clinical Protocol and Data Management component of the Cancer Therapy &Research Center (CTRC) includes the Clinical Trials Office (CTO) and Data and Safety Monitoring Committee (DSMC) activities including the Quality Assurance Division (QAD). The CTO provides central management, research support and oversight functions for the conduct of cancer-related clinical trials at the CTRC. CTO services are available to all members of CTRC engaged in clinical research;however some researchers elect to use research staff within their departments working in concert with CTO to provide umbrella oversight. The major functions of the CTRC CTO are to: Facilitate timely activation and administration of clinical trials, including preparations and communications required for scientific, ethical, operations and logistics reviews Ensure the research team is adequately trained to support each trial Maintain a centralized web-based repository of all protocol specific documents and consents Provide clinical assistance to facilitate the conduct of clinical trials including but not limited to enrollment and verification of patient eligibility, scheduling of appropriate tests, treatments, and assessments Provide data management support for clinical trials The QAD is separate from the CTO to minimize conflicts. Working with the DSMC, the functions of the QAD are to: Ensure that all reports, including reports of serious adverse events and unanticipated problems, are submitted in accordance with appropriate guidelines. Ensure protocol compliance with institutional policies and agreements, state and federal regulations, data accuracy and data integrity through a system of monitoring and quality assurance Provide training and education regarding best practices in conducting clinical trials to investigators and staff.
The Cancer Therapy &Research Center Clinical Trials Office and Quality Assurance Division are committed to providing effective and efficient infrastructure to support the clinical research efforts of the Center.
|Bandyopadhyay, Abhik; Favours, Edward; Phelps, Doris A et al. (2018) Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer 65:|
|Azpurua, Jorge; Mahoney, Rebekah E; Eaton, Benjamin A (2018) Transcriptomics of aged Drosophila motor neurons reveals a matrix metalloproteinase that impairs motor function. Aging Cell 17:|
|Gorthi, Aparna; Romero, July Carolina; Loranc, Eva et al. (2018) EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature 555:387-391|
|Yu, Xiaojie; Zhang, Yiqiang; Cavazos, David et al. (2018) miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis 9:193|
|Chen, Chen; Zhao, Shujie; Karnad, Anand et al. (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64|
|Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432|
|Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289|
|Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :|
|Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396|
|Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152|
Showing the most recent 10 out of 989 publications